Market Data
News
Tools
Markets
Discover
Subscribe Login/Register
FTSE 100
7,603.62
(
-0.31%
)
Dow Jones
33,093.34
(
1.0%
)
Gold vs US Dollar
1,938.07
(
-0.3%
)
Brent Oil
76.515
(
-0.76%
)
Bitcoin
27,817.24
(
0.26%
)
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Tissue Regenix Group Plc (TRX)

  7. Tissue Regenix Group Plc (TRX) Share Price

TRX

Tissue Regenix Group Plc

51.00
0.00 (0.0%)
Upgrade to Real-Time
Share Name Share Symbol Market Type Share ISIN Share Description
Tissue Regenix Group Plc LSE:TRX London Ordinary Share GB00BNTXR104 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
Upgrade Icon
  0.00 0.0% 51.00 0.00 08:00:00
Bid Price Offer Price High Price Low Price Open Price
50.00 52.00 51.00 51.00 51.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceutical Preparations 24.48 -2.70 - - 3,588.26
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 51.00 GBX
Related Shares
Astrazeneca (AZN), Gsk (GSK), Fusion Antibodies (FAB), Yourgene Health (YGEN)

Tissue Regenix (TRX) Latest News

Tissue Regenix News

Date Time Source Headline
25/5/202310:45ALNCNewsIN BRIEF: Tissue Regenix signs multi-year distribution contract
25/5/202307:00UKREGTissue Regenix Group PLC Distribution agreement with Australian Allografts
09/5/202312:00UKREGTissue Regenix Group PLC Holding(s) in Company
27/4/202312:35UKREGTissue Regenix Group PLC Result of AGM, Share Reorganisation &TVR
18/4/202318:49ALNCNewsTRADING UPDATES: FireAngel signs two delivery and production deals
18/4/202307:00UKREGTissue Regenix Group PLC Proposed Share Reorganisation Timetable
05/4/202307:00UKREGTissue Regenix Group PLC CEO and CFO Share Purchases
30/3/202307:00UKREGTissue Regenix Group PLC Holding(s) in Company
21/3/202312:37ALNCNewsIN BRIEF: Tissue Regenix reports narrowed loss and higher revenue
21/3/202307:00UKREGTissue Regenix Group PLC Final results for the year ended 31 December 2022

Tissue Regenix (TRX) Discussions and Chat

Tissue Regenix Forums and Chat

Date Time Title Posts
25/5/202309:27Tissue Regenix delivering practical solutions to real clinical issues7,676
27/9/202118:42Tissue Regenix takes pole position in regeneration game2
26/5/202013:31Torex with Charts & News14
15/1/202007:09TOREX 2007 - THE TILLS RING AT LAST13
14/1/202020:51Terrane Minerals- Cu explorer, trading in Canada17

Add a New Thread

Tissue Regenix (TRX) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type

Tissue Regenix (TRX) Top Chat Posts

Top Posts
Posted at 25/5/2023 09:27 by cliffpeat
A bit puzzled by - but interested in - the Australian Allograft (AA) deal.

As I understand it, the TRX products are synthetic and replace the need for allografts. See: hTTps://www.tissueregenix.com/orthopaedics/orthopure-xt/orthopure-xt-overview/

On the AA web site they claim:

"We keep it Australian

We pride ourselves on our high-quality, Australian products. We have partnered with PlusLife so there is no need to import and then distribute products from overseas."

They have a page on "Synthetics"
hTTps://australianallografts.com.au/synthetics/

Which simply states "Coming soon"

Does anyone know more about AA - it appears to be ambitious but seems to be based in a "co-working space" in Melbourne at the moment. Andrew Lambing's LinkedIn suggests he is self employed at AA since October 2019 marketing human tissue through a national team of agents.

It appears that AA is already a customer of TRX - see the quote from Kirsten Lund (of TRX) here: hTTps://www.proactiveinvestors.co.uk/companies/news/1016035/tissue-regenix-inks-australian-deal-1016035.html

""This new contract for clinical trial services again represents significant repeat business from an existing customer and we believe there is potential to expand the relationship further.

"These new assays also provide an important addition to our pharma services menu where our unique solution has already generated a high level of interest from new potential customers."

sp just nudged up a tad this morning and like other recent announcements this seems like "ground bait" for the enticement of future commercial "fish".

We shall see.

DYOR
Read Full Thread
Follow
Reply
Posted at 09/5/2023 11:37 by clocktower
To invest in increased production and China may require extra funds, and the consolidation might have in part been to make it easier to access extra funding at a discount to the current share price I guess impo but DYOR.
Read Full Thread
Follow
Reply
Posted at 21/4/2023 18:04 by cliffpeat
@longshanks

:)

Know what you mean but Del boy is a fictional character and seldom "lucky".

AND the re-positioned share price may attract more "serious" investors and add market-liquidity from which we may benefit in the near term.

We shall see??

hTTps://www.youtube.com/watch?v=63rcdLeXiU8&t=39s
Read Full Thread
Follow
Reply
Posted at 14/4/2023 21:18 by pj84
I have my suspicions on the blue down tick poster who doesn't want this to be the start of a new move up in the share price and I accept my post 7618 is clearly my own positive opinion, which they are perfectly entitled to disagree with, but I do find it strange that they also down ticked my previous post 7615 which is a factual post based on the recently published accounts!
Read Full Thread
Follow
Reply
Posted at 13/4/2023 11:25 by pj84
It is up marginally on September from £110m to £112m

hTTps://hardmanandco.com/research/corporate-research/operating-leverage/

Investment summary: TRX has a broad portfolio of innovative regenerative products that are in demand from surgeons. Completion of Phase 1 of its capacity expansion programme and reorganisation of the whole facility have led to operating efficiencies and comfort of supply to distribution partners. In our opinion, TRX is well-positioned to deliver persistently strong sales growth, which will drive margin expansion and highlight the low rating of the shares. An EV/sales multiple of 4x 2023E sales generates a valuation of $122m/£110m.
Read Full Thread
Follow
Reply
Posted at 13/4/2023 11:19 by pj84
Not sure that is correct as the valuation Hardman put on it this year is £112m and last year it was £20m less at £92m.

hTTps://hardmanandco.com/research/corporate-research/on-pathway-to-sustainability/

Investment summary: TRX has a broad portfolio of innovative regenerative products that are in demand from surgeons. Completion of Phase 1 of its capacity expansion programme has comforted distribution partners and provided positive momentum. We believe TRX is well-positioned to deliver strong sales growth, which will drive margin expansion and highlight the low rating of the shares. An EV/sales multiple of 4x 2023E sales generates a valuation of $120m/£92m.
Read Full Thread
Follow
Reply
Posted at 27/3/2023 16:04 by clocktower
The chart is not looking good either is it ?

Once consolidated I expect it to slide further as liquidity drys up.

I could understand it if they had already turned to a profitable business and if the share price was over 2p with a strong forward statement but not now.

You may harp on how good this is but the facts of the slide in share price speaks volumes.

I will even revise my target down now.
Read Full Thread
Follow
Reply
Posted at 24/3/2023 13:48 by timmy40
There are not many companies on AIM whose shares are priced at a fraction of a penny, certainly those wanting to be taken seriously by market institutions, rather than just punters.It's an easy win for management to get the share price higher and more marketable. They are ambitious and want to grow this company, i.e. The 4 S strategy ! All v positive.I'm sure management has been guided by the nominated broker/advisor to undertake this consolidation and would have spoken with the largest shareholders who have approved it too!It still needs approval at the AGM, but the management is doing a good job and should be trusted imo.
Read Full Thread
Follow
Reply
Posted at 23/3/2023 15:53 by timmy40
Sorry I cannot see this back at 0.50, the results were positive with +20% revenue across all divisions + cash in the bank to get to break even. The company is growing revenue in existing markets, particularly the US, as elective surgeries return/increase in frequency after Covid. They are expanding to new geographies/markets too, most probably China/Asia in the near future.The consolidation is required given the share price/no of shares in issue. A higher share price will mean the company is more marketable to institutions. It is v common in the US, which is the largest market by far for TRX and their board are Americans ? There is no dilution overall. This is all v good news. TRX's management are doing an excellent job but just imo.
Read Full Thread
Follow
Reply
Posted at 11/8/2022 11:11 by livewireplus
:-)) unfortunately no refunds ... but had some good times ... have ended-up married - but as wife earns more than me then can't complain .... pass the Tissue from the left-hand side. An interesting week so far for the TRX share price ....
Read Full Thread
Follow
Reply
Tissue Regenix share price data is direct from the London Stock Exchange
Your Recent History
LSE
TRX
Tissue Reg..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com

V: D: 20230530 07:19:38